143174-02-1

Basic information

• Product Name: Benzonitrile, 3-amino-4-(ethylamino)- (9CI)
• Synonyms: Benzonitrile, 3-amino-4-(ethylamino)- (9CI)
• CAS NO: 143174-02-1
• Molecular Formula: C₉H₁₁N₃
• Molecular Weight: 161.20374
• Product Categories: AMINESECONDARY
• Mol File: 143174-02-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzonitrile, 3-amino-4-(ethylamino)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 3-amino-4-(ethylamino)- (9CI)(143174-02-1)
• EPA Substance Registry System: Benzonitrile, 3-amino-4-(ethylamino)- (9CI)(143174-02-1)

Safety Data

• Hazardous Substances Data: 143174-02-1(Hazardous Substances Data)

Upstream product

• 1009-35-4 4-fluoro-3-nitrobenzonitrile 
• 939-80-0 4-chloro-3-nitrobenzonitrile 
• 90349-18-1 4-(ethylamino)-3-nitrobenzonitrile 

Downstream Products

• 562825-51-8 1-benzyl-3-(5-cyano-2-ethylaminophenyl)thiourea 

Relevant articles and documents

Small Sequence-Sensitive Compounds for Specific Recognition of the G?C Base Pair in DNA Minor Groove

A series of small diamidines with thiophene and modified N-alkylbenzimidazole σ-hole module represent specific binding to single G?C base pair (bp) DNA sequence. The variation of N-alkyl or aromatic rings were sensitive to microstructures of the DNA minor

Synthesis, DNA binding and antitrypanosomal activity of benzimidazole analogues of DAPI

A series of novel benzimidazole diamidines were prepared from the corresponding dicyano analogues either by applying Pinner methodology (5a–c, 10 and 13a) or by making amidoximes intermediates that were reduced to the corresponding amidines (15a–c). The n

Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity

We report here a novel series of benzimidazole sulfonamides that act as antagonists of the S1P1 receptor, identified by exploiting an understanding of the pharmacophore of a high throughput screening (HTS)-derived series of compounds described previously. Lead compound 2 potently inhibits S1P-induced receptor internalization in a cell-based assay (EC50 = 0.05 μM), but has poor physical properties and metabolic stability. Evolution of this compound through structure-activity relationship development and property optimization led to in vivo probes such as 4. However, this compound was unexpectedly found to be a potent CYP3A inducer in human hepatocytes, and thus further chemistry efforts were directed at addressing this liability. By employing a pregnane X receptor (PXR) reporter gene assay to prioritize compounds for further testing in human hepatocytes, we identified lipophilicity as a key molecular property influencing the likelihood of P450 induction. Ultimately, we have identified compounds such as 46 and 47, which demonstrate the desired S1P1 antagonist activity while having greatly reduced risk of CYP3A induction in humans. These compounds have excellent oral bioavailability in preclinical species and exhibit pharmacodynamic effects of S1P1 antagonism in several in vivo models following oral dosing. Relatively modest antitumor activity was observed in multiple xenograft models, however, suggesting that selective S1P1 antagonists would have limited utility as anticancer therapeutics as single agents.

HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS

Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more sy

Synthesis of some new 2-substituted-phenyl-1H-benzimidazole-5-carbonitriles and their potent activity against Candida species

New 2-substituted-phenyl-1H-benzimidazole-5-carboxylic acids (35, 38), ethyl-5-carboxylate (36), -5-carboxamides (37, 39),-5-carboxaldehyde (42), -5-chloro (40), -5-trifluoromethyl (41), and -5-carbonitriles (44-53, 55-67), -6-carbonitrile (54) were prepa